TCR-β transgenic mice fail to mediate a GVHR due to defects of allorecognition and subsequent IL-2 generation

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 835-842

  Rimm, I J ^a,b,d   Krenger, W ^a,b   Beland, J L ^a,b   Geller, M C ^a,b   Di Savino, E ^a,b   Yui, K ^c   Katsumata, M ^c   Ferrara, J L M ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bone marrow transplantation; Graft versus host disease; Transgenic mice

Indexed keywords

ALLOANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; GRAFT VS HOST REACTION; H-2 ANTIGENS; INTERLEUKIN-2; ISOANTIGENS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 0029993325     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Listman JL, Rimm IJ, Wang Y et al. Plasticity of the T cell receptor repertoire in TCR β-chain transgenic mice. Cell Immunol 1996; 167: 44-55.
2. Fenton RG, Marrack P, Kappler JW et al. Isotypic exclusion of γδ cell receptors in transgenic mice bearing a rearranged β chain gene. Science 1988; 241: 1089-1092.
3. Rimm IJ, Fruman DA, Abhyankar S et al. TCR-β transgenic mice have selective deficits in γδ cell subpopulations. Transplant Immunol 1994; 2: 218-224.
4. Uematsu Y, Ryser S, Dembic Z et al. In transgenic mice the introduced functional T cell receptor β gene prevents expression of endogenous β genes. Cell 1988; 52: 831-841.
5. a encoded antigens in T cell receptor β-chain transgenic mice. EMBO J 1989; 8: 719-727.
6. Rimm IJ, Ghayur T, Gasser DL et al. Alloreactive lymphocytes from T cell receptor (β-chain) transgenic mice do not mediate graft-versus-host disease. J Immunol 1991; 146: 1130-1133.
7. Barrett LV, Rimm IJ, Wiens GR et al. Allorecognition in T-cell receptor (β-chain) transgenic mice. Surgery 1991; 110: 385-388.
8. Kikly K, Dennert G. Evidence for a role of T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. J Immunol 1992; 149: 3489-3494.
9. Perkins DL, Wang Y, Fruman D et al. Immunodominance is altered in T cell receptor (β-chain) transgenic mice without the generation of a hole in the repertoire. J Immunol 1991; 146: 2960-2964.
10. Kuchroo V, Collins M, Al-Sabbagh A et al. Susceptibility to experimental allergic encephalomyelitis: critical effect of T cell receptor repertoire and antigen. J Exp Med 1994; 179: 1659-1664.
11. Uematsu Y. Preferential association of α and β chains of the T cell antigen receptor. Euro J Immunol 1992; 22: 603-606.
12. Ivars F. T cell subset-specific expression of antigen receptor β chains in α chain-transgenic mice. Euro J Immunol 1992; 22: 635-639.
13. Yui K, Komori S, Katsumata M et al. Self-reactive T cells can escape clonal deletion in T-cell receptor Vβ8.1 transgenic mice. Proc Natl Acad Sci USA 1990; 87: 7135-7139.
14. 4. Nature 1990; 345: 540-542.
15. Berg LJ, Pullen AM, Fazekas de St Groth B et al. Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell 1989; 58: 1035-1046.
16. Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature 1977; 268: 154-156.
17. Ohara J, Paul WE, Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 1985; 315: 333-336.
18. Marshak-Rothstein A, Fink P, Gridley T et al Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus. J Immunol 1979; 122: 2491-2497.
19. Billingham RE. The biology of graft-versus-host reactions. The Harvey Lectures 1966; 62: 21-78.
20. Kubo RT, Born W, Kappler JW et al. Characterization of a monoclonal antibody which detects all marine α/β T cell receptors. J Immunol 1989; 142: 2736-2742.
21. Ghayur T. Seemayer TA, Lapp WS. Association between the degree of thymic dysplasia and the kinetics of thymic NK cell activity during the graft-versus-host reaction. Clin Immunol Immunopathol 1988; 48: 19-30.
22. McCarthy P, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
23. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 1981; 126: 1614-1619.
24. Perkins DL, Wang Y, Wiens GR et al. Superantigen induced peripheral tolerance inhibits T cell responses to immunogenic peptides in T cell receptor (β-chain) transgenic mice. J Immunol 1993; 150: 4284-4291.
25. Yui K. Bhandoola A, Radic MZ et al. Inhibition of abnormal T cell development and autoimmunity in gld mice by transgenic T cell receptor β chain. Euro J Immunol 1992; 22: 1693-1700.
26. Theobald M, Nierle T, Bunjes D et al. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. New Engl J Med 1992; 327: 1613-1617.
27. DeGast GC, Mickelson EM, Beatty PG et al. Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia. Bone Marrow Transplant 1992; 9: 87-90.
28. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664-672.
29. Hakim FT, Sharrow SO, Payne S, Shearer GM. Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J Immunol 1991; 146: 2108-2115.
30. Sykes M, Abraham VS, Harty MW, Pearson DA. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993; 150: 197-205.
31. Blazar BR, Taylor PA, Vallera DA. In vivo or in vitro antiCDSε chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. J Immunol 1994; 152: 3665-3674.
32. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. J Exp Med 1978; 148: 1687-1698.
33. Fowler DH, Kurasawa K, Husebekk A et al. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol 1994; 152: 1004-1013.
34. Kohler PC, Erickson C, Finlay JH et al. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease. Cancer Res 1986; 46: 5413-5418.
35. Cray C, Levy R, CD8+ and CD4+ T cells contribute to the exacerbation of Class I MHC disparate graft-vs-host reactions by concurrent murine cytomegalovirus infection, Clin Immunol Immunopathol 1993; 67: 84-90.
36. Truitt RL, Atasoylu AA, Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51-58.
37. Fruman DA, Burakoff SJ, Bierer BE, Molecular actions of cyclosporin A. FK506 and rapamycin. In: Thomson AW, Starzl TE (eds). Immunosuppressive Drugs: Developments in Anti-rejection Drugs. Edward Arnold: Boston, 1994, pp 15-35.
38. Sigal NH, Dumont FJ, Cyclosporin A, FK-506, and rapamycin. In: Paul WE, Fathman CG. Metzger H (eds.). Annual Review of Immunology, vol. 10. Annual Reviews, Inc: Palo Alto, California, 1992, pp 519-560.
39. Kirkman RL, Barrett LV, Gaulton GN et al. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358-362.
40. Tinubu SA, Hakimi J, Kondas JA et al. Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. J Immunol 1994; 153: 4330-4338.
41. Ferrara JLM, Marion A, McIntyre JF et al. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874-1877.
42. Volk H-D, Brocke S, Osawa H, Diamantstein T. Suppression of the local graft-vs-host reaction in rats by treatment with a monoclonal antibody specific for the interleukin 2 receptor. Euro J Immunol 1986; 16: 1309-1312.
43. Anasetti C, Hansen JA, Waldmann TA et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320-1327.
44. Herve P, Widjenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017-1023.
45. Blackman MA, Finkel TH, Kappler J et al. Altered antigen receptor signaling in anergic T cells from self-tolerant T-cell β-chain transgenic mice. Proc Natl Acad Sci USA 1991; 88: 6682-6686.
46. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
47. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518-1523.
48. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs host disease. J Exp Med 1987; 166: 1280-1289.
49. Dalton DK, Pitts-Meek S, Keshav S et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993; 259: 1739-1742.